// App-Quantinova.ai

TPS8059 : Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Researchers

Presenter

  • Pieter Sonneveld

Principal Investigators

  • Evangelos Terpos

  • Meletios A. Dimopoulos

  • Jon Ukropec

  • Elena Smith

  • Nienke Houkes

  • Jordan Mark Schecter

  • Efstathios Kastritis

Medical Centers

  • Department of Hematology, Erasmus MC Cancer Insitute, Rotterdam, Netherlands

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Research & Development, High Wycombe, United Kingdom

  • Janssen Research & Development, Leiden, Netherlands

  • Janssen Research & Development, LLC, Raritan, NJ

Locations

  • United States

  • United Kingdom

  • Greece

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Diphenhydramine

  • Derma-Pax lotion

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Acetaminophen

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03180736

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved